Table 3:
DFSP treated with imatinib: response rate, adverse events and follow-up.
| Author | Dose | CR | PR | SD¶ | Progression¶ | Duration | Median treatment duration (m, range) | Median follow-up (months) |
|---|---|---|---|---|---|---|---|---|
| Ugurel et al | 600 mg/d | 0 | 50% (7/14) | 35.7% (5/14) | 14.2% (2/14) | ≥ 6 weeks | 3.1 months (1.5 – 16.7) | 76.7 months (46.7 – 97.3+) |
| Wang et al | 400 mg/d, increased to 800 mg/d if progression | 0 | 68.1% (15/22) | 27.2% (6/22) | 4% (1/22) | N/A | 15 months (1 – 43) | 36 months (6 – 81) |
| Rutkowski et al | 800 mg/d | 0 | 68% (21/31) | 19% (6/31) | 13% (4/31) | N/A | N/A | 63.5 months |
| Stacchiotti et al | 400 mg/d, increased to 800 mg/d if progression | 0 | 80% (8/10) | 10% (1/10) | 10% (1/10) | N/A | N/A | N/A |
| Kerob et al | 600 mg/d | 0 | 36% (9/25) | 64% (16/25)†† | 0 | Up to 8 weeks | N/A | N/A |
| Heinrich et al* | 800 mg/d | 33% (4/12) | 50% (6/12) | 0 | 8.3% (1/12) | N/A | N/A | N/A |
| McArthur et al | 800 mg/d | 40% (4/10) | 50% (5/10) | 0 | 10% (1/10) | 4.6 months (0.6 – 22.9) | 4.7 months (0.69 – 22.9) | 10.6 months (1 – 27.7) |
| Han et al | 800 mg/d | 0 | 100% (4/4) | 0 | 0 | Until tumor size stabilized and continued 4 weeks after surgery | 3 months (3 – 7) | 18 – 48 months |
| Rutkowski et al - EORTC** - SWOG** |
• 800 mg/d • 400 mg/d, (increased to 800 mg if no response) |
• 0 • 0 |
• 31.3% (5/16) • 50% (4/8) |
• 37.5% (6/16) • 25% (2/8) |
• 18.7% (3/16) • 12.5% (1/8) |
• 14 weeks • 48 weeks |
• 9.2 months (0.1 – 40) • 10 months (3.6 – 11.3) |
• 31.2 months (26.4 – 35.7) • 31.2 months (26.4 – 35.7) |
| Systematic review † | 5.2% (8/152) | 55.2% (84/152) | 27.6% (42/152) | 9.2% (14/152) | Calculated mean: 12 months (0.1–43) | 39.8 months (1 – 97.3+)*** |
¶
Some articles stated “no response” instead of “stable disease” or “progression”; in those cases we further included them on stable disease or progression group accordingly.
*
One patient had an unknown response
**
Two patients were not evaluable in the EORTC group and 1 in the SWOG group.
†
The different response rates sum does not add to 100% due to exclusion of 4 patients in different studies (see above).
††
The authors referred as “Non-respondents” (<30% decrease in size), thus we interpreted as stable disease.
***
Average mean was calculated from medians.
N/A data not available in the study, CR: complete response, PR: partial response, SD: stable disease.